All posts by admin

25Mar/14

Shoemaker talks about daughter's death and organ donations – Hudson Star Observer


Hudson Star Observer

Shoemaker talks about daughter’s death and organ donations
Hudson Star Observer
He said many people think there are enough donors when you add the numbers, but many don’t realize that it takes unique circumstances surrounding the death. The victim has to die a certain way – usually brain death.” He said out of 100,000 deaths of …

and more »

25Mar/14

Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular – Terra Argentina

Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular
Terra Argentina
En un ensayo clínico, la terapia de mantenimiento con rituximab redujo la ansiedad asociada con el cáncer frente a la espera vigilada en pacientes sin síntomas con linfoma folicular “no voluminoso” avanzado. El fármaco también difirió la necesidad de …

25Mar/14

Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular – Terra Perú

Ensayo indica Rituximab alivia la ansiedad en pacientes con linfoma folicular
Terra Perú
En un ensayo clínico, la terapia de mantenimiento con rituximab redujo la ansiedad asociada con el cáncer frente a la espera vigilada en pacientes sin síntomas con linfoma folicular “no voluminoso” avanzado. El fármaco también difirió la necesidad de …

and more »

25Mar/14

UPDATE 2-FDA staff review recommends against Novartis heart failure drug – Reuters


News Tonight Africa

UPDATE 2-FDA staff review recommends against Novartis heart failure drug
Reuters
“We recommend that serelaxin not be approved at this time because there is insufficient evidence to support the proposed indication to “improve the symptoms of acute heart failure through reduction of the rate of worsening of heart failure,” the
FDA Reviewers Recommend Against Approval For Novartis Heart Failure DrugForbes
FDA Staff Recommends Rejection of Novartis Heart-Failure DrugWall Street Journal
More bad news for Novartis on heart failure candidatePMLiVE
GlobalPost
all 28 news articles »
25Mar/14

FDA Reviewers Recommend Against Approval For Novartis Heart Failure Drug – Forbes


Headlines & Global News

FDA Reviewers Recommend Against Approval For Novartis Heart Failure Drug
Forbes
On Thursday the FDA’s Cardiovascular and Renal Drugs Advisory Committee will discuss the biologics license application (BLA) for serelaxin injection (proposed trade name Reasanz) from Novartis. The indication is for the improvement of the symptoms of 
FDA staff review recommends against Novartis heart failure drugReuters India

all 13 news articles »